Combinations of agents have replaced sunitinib as first-line therapy for advanced renal-cell cancer. Laura Wood, RN, MSN, OCN; Megan Price, MSN, APRN, FNP-C; and Virginia Seery, MSN, RN, ANP-BC, AOCNP, discuss their best practices for helping patients get the most benefit out of combination therapy for their advanced renal-cell cancer diagnosis.
Baylor Charles A. Sammons Cancer Center
Dallas, TX
Dallas, TX
Beth Israel Deaconess Medical Center
Boston, MA
Boston, MA
Cleveland Clinic Taussig Cancer Center
Cleveland, OH
Cleveland, OH
Related Items
Videos published on December 19, 2023 in Interview with the Innovators
Videos published on December 18, 2023 in Interview with the Innovators